Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
  • A61K31/05—Phenols
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/14—Macromolecular materials
  • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
  • A61L27/24—Collagen
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/14—Macromolecular materials
  • A61L27/26—Mixtures of macromolecular compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
  • A61L27/54—Biologically active materials, e.g. therapeutic substances
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
  • A61L27/56—Porous materials, e.g. foams or sponges
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
  • A61L27/60—Materials for use in artificial skin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
  • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
  • A61L2300/428—Vitamins, e.g. tocopherol, riboflavin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
  • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
  • A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
  • A61L2300/622—Microcapsules

Definitions

• This invention is related to dermal matrices and production method thereof used in treating chronic wounds, which enables the speedy repair of the dermal tissue, and which comprises within its structure micro particles having antioxidant agents with synergistic effects.
• micro particle systems and matrix systems provide advantageous treatment methods when compared with the prior art methods.
• matrices comprising agents that help heal the area, and which provide the necessary mechanical support, compensating via and occlusive effect the lost tissue area as a result of various injuries.
• Dermal matrices have been prepared especially comprising collagen-chitosan, collagen-gelatin, collagen-glycosaminoglycans, and collagen- hyaluronic acid compositions and by incubating fibroblast to these and healing of the wound tissue has been observed.
• Dermal matrices are systems prepared with natural or synthetic polymers in order to effectively support cell growth and development and the usage of these in treating wounds have opened up a new horizon.
• the main aim of these structures is to redevelop the tissue that has been damaged and to carry different biomaterials and bioactive molecules to this region.
• the wound area is open to infection and similar complications and the most effective approach in preventing the infections are to provide effective treatment as soon as possible.
• the first six hours is the more important time span in terms of bacterial colonization formation after getting wounded.
• the most effective method in preventing infections are to seal off the wound by using sterile patches over the wounds and cleaning the wound under aseptic conditions before sealing it with a sterile patch, these conditions are even more effective than antibiotic treatment. For this reason, immediately covering the wound, increasing the self repair of the dermal layer, and developing fully layered tissues that shall replace the tissue area are some of the crucial subjects that need to be addressed in the current studies.
• graft transfer which is another treatment carried out in case of large tissue loss cases also has many disadvantages.
• These disadvantages can be diseases that are transmitted from the donor, or formation of new wounds at the donor area from which the graft was taken from.
• autografts are materials that are preferred, in some cases there may not be any suitable skin tissue that can be transferred in patients.
• a new wound is present at the area where the graft tissue is taken from.
• Another disadvantage is that these procedures may necessitate surgical operations.
• innovative approaches were deemed necessary to shorten the treatment time, in order to prevent complications such as infections and in order to overcome said disadvantages.
• the methods used to ensure that the dermal matrices prepared using collagen were three dimensional comprising chemical materials ruin the conditions that need to be present for cell growth.
• the products developed to reach said aims do not comprise micro particles and they act like a wound patch wherein cells can grow a little bit faster.
• the aim of the present invention is to provide a dermal matrix, which increases the efficiency of chronic wound treatments and decreases the time of healing and ensures tissue repair.
• Another aim of the invention is to provide a dermal matrix not only comprising collagen and laminin but also comprising micro particles which carry antioxidant agents that help to speed up tissue repair speed by showing synergic effects.
• Another aim of the invention is to obtain a dermal matrix production method that enables tissue repair, wherein agents formed of proteins located inside the natural structure of the dermis and other components are used.
• Another aim of the invention is to provide a dermal matrix production method which supports cell growth and tissue repair, by means of using the cross linking method which is not a chemical method.
• Another aim of the invention is to provide a dermal matrix production method which enables tissue repair and prevents heat sensitive bio materials from degrading by applying a lyophilisation procedure.
• a dermal matrix production method that provides tissue repair produced in order to reach the aim of this invention has been shown in the attached figure, wherein said figure illustrates the following;
• Figure 1 - Is the flow chart of the method subject to the invention.
• the method (10) subject to the invention is principally based on preparing a dermal matrix system and a micro particle system separately and following this spraying the micro particle onto the dermal matrix thus combining these two systems physically.
• a collagen solution is prepared (111) by adding collagen to acidic acid solution in order to prepare a dermal matrix system (11).
• bovine collagen is added (1 1 1) at a concentration of 0, 1% to 0.1 M acidic acid solution.
• the collagen solution (1 12) Following this laminin is added onto the collagen solution (1 12).
• 2.5ml of the collagen solution that has been prepared is taken and 20 ⁇ 1 laminin is added, and all of it is mixed in an ice bath (1 12).
• the ice bath it is aimed to prevent the deterioration of the protein structures that are present inside the mixture.
• mixing is carried out at a speed of 3000 cycles/minute, for 1 minute, using a 10-G probe.
• the mixture comprising collagen and laminin is left to wait for 12 hours at a temperature of -20 ⁇ 1 °C and is frozen (113). Following this, said mixture which has been frozen is subjected to lyophilization for 24 hours (114). Thereby it is ensured that the deterioration of the heat sensitive biomaterials inside said mixture is prevented.
• the lyophilisate structure comprising collagen and laminin that has been obtained is cross linked (115) under 254nm wavelength using an ultraviolet cross binder (UV-cross linker) device.
• an aqueous polymer solution is prepared (121) in order to provide the formation of micro particles (12).
• HA hyaluronic acid sodium salt
• dipalmitoylphosphatidylcholine (DPPC) and resveratrol is mixed into alcohol and is dissolved (122).
• DPPC dipalmitoylphosphatidylcholine
• resveratrol is mixed into alcohol and is dissolved (122).
• 0.7-0.75 g DPPC and 0.05- 0.1 g resveratrol 350 ml is added into ethanol and is mixed (122).
• the HA solution (121) that has been prepared is added onto the solution (122) of DPPC and resveratrol in alcohol and is mixed at 40 ⁇ 1°C (123).
• the whole mixture that has been prepared is placed inside a spray dryer and micro particles are obtained by spraying (124).
• the spray dryer has been adjusted such that the initial temperature is 180°C, and the spraying speed is 400 L/h.
• HA micro particles loaded with resveratrol and prepared with a spray dryer are sprayed onto the previously prepared dermal matrix (1 1) as dry powder and said two systems are combined (13).
• the sprayed micro particles comprise 50 ⁇ resveratrol.
• the average diameter of the obtained dermal matrix is 2.24 ⁇ 0.05 cm and their thicknesses have been measured as 0.23 ⁇ 0.04 cm.
• a TA-XT plus texture analysis device has been used in order to determine the mechanical characteristics of dermal matrices.
• the hardness 26-21 N, compression 23-18 N/mm, cohesion 0.93-1 and elasticity values 0.8-1 have been calculated by way of power, time curves that belong to the matrix.
• the humidity amount of the dermal matrix subject to the invention has been calculated as 0.2%.
• the sizes of the micro particles located inside the dermal matrix have been calculated to be between 15-30 ⁇ using the laser diffraction method.
• the formulations are spherical and have smooth surfaces.
• the particles sizes observed through SEM have been compared with the results of the previously carried out laser diffraction distribution method, and the sizes have been found to be consistent.
• the drug loading capacity of the micro particles that have been prepared has been calculated as 0.5-lmg and the encapsulation efficiency have been calculated to be between %97-%98.7.
• active agent release studies have been carried out from micro particle formulations prepared with different resveratrol concentrations. The results of the analysis showed that the released resveratrol amount from the formulations for 24 hours were between %73-85.
• the effect of hyaluronidase, collagenase, lipase and phospholipase enzymes in relation to release of resveratrol from micro particles was examined.
• Confocal microscope 3D software program has been used in order to determine if the micro particles were homogenously distributed in the dermal matrix and where they were localized. The confocal study was renewed and the data have been evaluated in this program. The morphological studies carried out showed that the micro particles were distributed much more homogeneously at the top surface of the dermal matrix and that said micro particles were in complete contact with the matrix.
• the human dermal fibroblast cells, (Invitrogen C-013-5C) were cultured in humid conditions comprising 37 ⁇ 0.5 °C and 5% C0 2 according to the instructions of the producer.
• Resveratrol solution has been incubated with formulations that did not comprise resveratrol and micro particle formulations that comprised resveratrol for 24 hours and the effects of all samples regarding cell vitality were examined.
• resveratrol solution or formulations that are empty or do contain active agents were observed not to have cytotoxic potential, and they have shown cell proliferation increasing effects in concentrations that are corresponding to 50 ⁇ resveratrol content.
• Oxidative stress parameters such as total glutation, malondialdehyde, and superoxide dismutase and glutation peroxidase have been examined inside the cells that have been analyzed. The results that were obtained, were an indication that the dosage type developed for resveratrol comprised oxidative activity at a molecular level.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Epidemiology (AREA)
• Dermatology (AREA)
• Transplantation (AREA)
• Oral & Maxillofacial Surgery (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Biophysics (AREA)
• Biomedical Technology (AREA)
• Molecular Biology (AREA)
• Dispersion Chemistry (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Preparation (AREA)
• Materials For Medical Uses (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Polymers & Plastics (AREA)
• Cosmetics (AREA)

Priority Applications (16)

Applications Claiming Priority (2)

Publications (1)

Family

ID=51619260

Family Applications (1)

Country Status (20)

Cited By (2)

Families Citing this family (1)

Citations (1)

Family Cites Families (8)

• 2013
  • 2013-07-25 TR TR2013/09048A patent/TR201309048A2/tr unknown
• 2014
  • 2014-07-07 LT LTEP14772477.7T patent/LT3024505T/lt unknown
  • 2014-07-07 PL PL14772477T patent/PL3024505T3/pl unknown
  • 2014-07-07 EP EP14772477.7A patent/EP3024505B1/en active Active
  • 2014-07-07 CN CN201480045631.3A patent/CN105492033B/zh not_active Expired - Fee Related
  • 2014-07-07 ES ES14772477T patent/ES2707698T3/es active Active
  • 2014-07-07 SI SI201431061T patent/SI3024505T1/sl unknown
  • 2014-07-07 AU AU2014293717A patent/AU2014293717B2/en not_active Ceased
  • 2014-07-07 CA CA2919422A patent/CA2919422C/en active Active
  • 2014-07-07 RU RU2016105242A patent/RU2673665C2/ru active
  • 2014-07-07 HR HRP20190132TT patent/HRP20190132T1/hr unknown
  • 2014-07-07 RS RS20190100A patent/RS58258B1/sr unknown
  • 2014-07-07 BR BR112016001573-8A patent/BR112016001573B1/pt not_active IP Right Cessation
  • 2014-07-07 US US14/907,563 patent/US9517215B2/en not_active Expired - Fee Related
  • 2014-07-07 WO PCT/TR2014/000251 patent/WO2015012775A1/en not_active Ceased
  • 2014-07-07 JP JP2016529742A patent/JP6530392B2/ja not_active Expired - Fee Related
  • 2014-07-07 DK DK14772477.7T patent/DK3024505T3/en active
  • 2014-07-07 HU HUE14772477A patent/HUE041810T2/hu unknown
  • 2014-07-07 PT PT14772477T patent/PT3024505T/pt unknown
• 2016
  • 2016-01-27 ZA ZA2016/00594A patent/ZA201600594B/en unknown

Patent Citations (1)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events